ANI Pharmaceuticals, a Baudette, Minnesota-headquartered pharmaceutical company, has acquired the new drug applications (NDA) and US rights to market four drugs from AstraZeneca for $46.5 million consisting of cash, royalties, and sales-based milestones.

The four drugs include: Atacand (candesartan cilexetil) and Atacand HCT (candesartan-hydrochlorothiazide), drugs for treating high blood pressure as well as the cancer drugs Arimidex (anastrozole) and Casodex (bicalutamide).

AstraZeneca will continue to market and supply the drugs outside of the US. The acquired assets include the NDAs for all four products and a license to their trademarks. The acquisitions were funded through a combination of cash and debt.

Collectively, these products generated approximately $19 million in US market sales during the trailing twelve months through October 2017, according to IQVIA (formerly QuintilesIMS Health) and as reported by ANI Pharmaceuticals

Source: ANI Pharmaceuticals